Does Mounjaro reduce cancer risk — and what does the evidence actually show?

What does the research actually show about tirzepatide and cancer risk?

A question our prescribers hear most weeks is whether losing weight on Mounjaro might lower cancer risk alongside improving blood pressure and blood sugar. The honest answer is: possibly, indirectly, but the science is not yet at the point where anyone should start tirzepatide primarily for that reason.

The strongest established link runs through body weight rather than the drug itself. The NHS notes that excess weight is associated with a higher risk of several cancers, including bowel, breast (post-menopause), womb, and kidney cancers, among others. If tirzepatide produces meaningful, sustained weight reduction (which the SURMOUNT-1 trial data summarised on our Mounjaro overview page show it can, at an average of around 20% of body weight at the highest dose) then some of that obesity-related risk burden may fall over time.

Separately, some observational and population-level analyses have looked at GLP-1 receptor agonists as a class and found signals worth investigating in relation to certain cancers. A widely discussed 2024 analysis suggested associations between semaglutide use and lower rates of some obesity-related cancers. Tirzepatide-specific cancer data are sparser still. Researchers are cautious because observational data cannot rule out confounding, people who access these medicines may differ systematically from those who do not. For a thorough look at what the data say specifically about tirzepatide, the tirzepatide and cancer risk page goes deeper into the study designs and their limitations.

The MHRA has not issued any guidance linking Mounjaro to cancer risk reduction, and NICE's appraisal of tirzepatide (TA1026) makes no cancer-related recommendation. Treat promising early signals as exactly that: signals, not conclusions.

Is there any concern that Mounjaro could increase cancer risk?

Preclinical (animal) studies of GLP-1 receptor agonists raised a theoretical concern about thyroid C-cell tumours, specifically medullary thyroid carcinoma. This signal emerged in rodent studies at doses far above clinical levels, and has not been confirmed in human data. The Mounjaro Summary of Product Characteristics on the electronic Medicines Compendium lists a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), as a contraindication. If either applies to you, tirzepatide is not suitable and your prescriber will identify that during the clinical review.

There is also an ongoing MHRA-mandated pharmacovigilance requirement under the Black Triangle (▼) status that Mounjaro carries. This means post-marketing safety data continue to be collected and reviewed, including any emerging cancer signals. Transparency about what is still being watched is part of responsible prescribing. For a fuller account of the cancer-risk questions specific to Mounjaro, see our detailed cancer risk page, which is updated as new data emerge.

The picture for other Mounjaro side effects is clearer and better characterised: the most common are gastrointestinal and tend to be mild and time-limited. Cancer risk sits in a different category (theoretical, monitored, not confirmed) and should neither be ignored nor overstated.

When should you get medical help, and how do you report a concern?

None of the established side-effect warnings for tirzepatide are cancer-related in the direct sense, but there are symptoms that should prompt urgent medical attention. Severe, persistent abdominal pain that spreads toward the back, with or without vomiting, may indicate pancreatitis, a known but infrequent GI complication; the MHRA highlighted this specifically in a Drug Safety Update in January 2026. Seek help promptly rather than waiting for a scheduled review.

More generally: any unexplained lump, persistent change in bowel habit, unexplained weight loss beyond what treatment would explain, or any symptom that concerns you warrants a GP visit, regardless of whether you are on tirzepatide. Do not assume a new symptom is a medicine side effect without getting it checked. Information on managing other side effects is on our guide to reducing Mounjaro side effects, and pancreatitis risk specifically is covered in detail at how to reduce the risk of pancreatitis on Mounjaro.

If you experience a suspected side effect (including anything unexpected) you can report it directly to the MHRA via the Yellow Card scheme. This applies to any patient, not just those in formal trials. Reports from real-world use are how post-marketing signals are identified, so filing one genuinely matters. If you have questions about your treatment or your personal risk profile, speak to our prescribers, suitability, health history and any concerns are all part of the consultation, not an afterthought.